晚期肝细胞癌联合选择性内放射治疗或索拉非尼单药治疗后的肝功能
SORAMIC试验的事后分析基于符合方案人群(SIRT+索拉非尼109例 vs 索拉非尼单药173例),用ALBI评分监测肝功能。SIRT+索拉非尼组ALBI评分升高更显著,且SIRT的生存获益仅见于<65岁、无肝硬化、Child-Pugh 5、未接受过TACE的患者。SIRT常对肝功能有负面且多亚临床的影响,可能损害预后。
要点
- SIRT+索拉非尼较索拉非尼单药更显著升高ALBI评分,提示肝功能损害。
- SIRT生存获益仅见于<65岁、无肝硬化、Child-Pugh 5、未接受TACE者。
- SIRT对肝功能的不良影响常为亚临床,需严格选择患者并优化技术。
核心结论
- SIRT常对肝细胞癌患者肝功能产生负面且多亚临床的影响,可能损害治疗后预后。
研究设计与样本
- 基于已发表的随机对照试验SORAMIC的符合方案人群分析,SIRT+索拉非尼组109例,索拉非尼单药组173例。
主要发现
- 随访期间所有患者组ALBI评分均升高,SIRT+索拉非尼组升高幅度高于索拉非尼组(第4个月p=0.0021,第6个月起p<0.0001)。
- SIRT+索拉非尼较索拉非尼单药在<65岁、无肝硬化、Child-Pugh 5、未接受过TACE的患者中带来生存获益。
- 在SIRT未改善生存的相反亚组中观察到ALBI评分升高更高:≥65岁(p<0.05)、肝硬化(p=0.07)、Child-Pugh 6(p<0.05)、既往TACE(p=0.08)。
关键数值与推荐
- 采用ALBI评分监测随访期间肝功能变化。
- SIRT+索拉非尼组与索拉非尼组ALBI评分升高差异:第4个月p=0.0021,第6个月起p<0.0001。
临床怎么用
- SIRT前应仔细选择患者,避免用于≥65岁、肝硬化、Child-Pugh 6或既往TACE者。
- 通过选择性治疗、高肿瘤摄取比和药物预防来预防临床及亚临床肝损伤,可能提高疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: SORAMIC is a previously published randomised controlled trial assessing survival in patients with advanced hepatocellular carcinoma who received sorafenib with or without selective internal radiation therapy (SIRT). Based on the per-protocol (PP) population, we assessed whether the outcome of patients receiving SIRT+sorafenib vs. sorafenib alone was affected by adverse effects of SIRT on liver function. METHODS: The PP population consisted of 109 (SIRT+sorafenib) vs. 173 patients (sorafenib alone). Comparisons were made between subgroups who achieved a significant survival benefit or trend towards improved survival with SIRT and the inverse group without a survival benefit: <65 years-old vs. ≥65 years-old, Child-Pugh 5 vs. 6, no transarterial chemoembolisation (TACE) vs. prior TACE, no cirrhosis vs. cirrhosis, non-alcohol- vs. alcohol-related aetiology. The albumin-bilirubin (ALBI) score was used to monitor liver function over time during follow-up. RESULTS: ALBI scores increased in all patient groups during follow-up. In the PP population, ALBI score increases were higher in the SIRT+sorafenib than the sorafenib arm (p = 0.0021 month 4, p <0.0001 from month 6). SIRT+sorafenib conferred a survival benefit compared to sorafenib alone in patients aged <65 years-old, those without cirrhosis, those with Child-Pugh 5, and those who had not received TACE. A higher increase in ALBI score was observed in the inverse subgroups in whom survival was not improved by adding SIRT (age ≥65 years-old, p <0.05; cirrhosis, p = 0.07; Child-Pugh 6, p <0.05; prior TACE, p = 0.08). CONCLUSION: SIRT frequently has a negative, often subclinical, effect on liver function in patients with hepatocellular carcinoma, which may impair prognosis after treatment. Careful patient selection for SIRT as well as prevention of clinical and subclinical liver damage by selective treatments, high tumour uptake ratio, and medical prophylaxis could translate into better efficacy. CLINICAL TRIAL NUMBER: EudraCT 2009-012576-27, NCT01126645 LAY SUMMARY: This study of treatments in patients with hepatocellular carcinoma found that selective internal radiation therapy (SIRT) has an adverse effect on liver function that may affect patient outcomes. Patients should be carefully selected before they undergo SIRT and the treatment technique should be optimised for maximum protection of non-target liver parenchyma.
引用
- Ricke J, Schinner R, Seidensticker M, et al. Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma. J Hepatol. 2021. PMID: 34454995. doi:10.1016/j.jhep.2021.07.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。